Abstract
A rapidly spreading novel corona virus infection, COVID-19 (Corona virus disease, 2019), a global pandemic has already reported to cause death of approximately 2.5% of total infected individuals. Being more immunodeficient uncontrolled diabetic individuals have more chance to be symptomatic with COVID-19 than the nondiabetic individuals. There are some recent updates regarding the efficacy of hydroxychloroquine as a monotherapy or with adjunct therapy to improves the condition of COVID-19 infected patients and even the molecule hasthe property to regulate blood glucose level without much hypoglycemia. This review article highlighted the proposed mechanisms of hydroxychloroquine by which it provides beneficial effect in nondiabetic individuals who became symptomatic with COVID-19 as well as being an approved anti diabetic agent how it reduces the chance of infection with COVID-19 in patients with diabetes.
Keyword: Hydroxychloroquine, Coronavirus, COVID-19, Diabetes.
References
- idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-for-people-with-diabetes.html
- Almazan, F., Gonzalez, J. M., Penzes, Z., Izeta, A., Calvo, E., Plana-Duran, J., et al. (2000). Engineering the largest RNA virus genome as an infectious bacterial artificialchromosome. Proc. Natl. Acad. Sci. USA97:5516–5521
- An, S., Chen, C. J., Yu, X., Leibowitz, J. L., and Makino, S. (1999). Induction of apoptosis inmurine coronavirus-infected cultured cells and demonstration of E protein as an apoptosis inducer. J. Virol.73:7853–7859.
- J. Bosch and P. Rottier Perlman, Gallagher, Snijder (Eds.), Mechanisms of coronavirus cell entry mediated by the viral spike protein Nidoviruses, ASM Press, Washington, D.C. (2008), pp. 157-178
- Belouzard, J.K. Millet, B.N. Licitra and G.R. Whittaker Mechanisms of coronavirus cell entry mediated by the viral spike protein Viruses, 4 (6) (2012), pp. 1011-1033
- Wu Z, McGoogan JM, Characteristics of and important lessons from the corona virus disease 2019 (COVID-19) outbreak in chains: summary of report of 72 312 cases from the Chinese centre for disease control and prevention. J Am Med Assoc 2020 Feb 24
- C. Nash and M.J. Buchmeier. Entry of mouse hepatitis virus into cells by endosomal and nonendosomal pathways. Virology, 233 (1) (1997), pp. 1-8.
- Yang X Yu Y Xu J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020.
- Guan W Ni Z Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020.
- Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 2016;291:9218e32.
- Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Drug treatment options for the 2019- new coronavirus (2019-nCoV). Biosci Trends 2020 Jan 28.
- Ohkuma S. & Poole B. Fluorescence probe measurement of the intralysomsomal pH in living cells and the perturbation of pH by various agents. Proc. Natl Acad. Sci. USA 75, 3327-3331 (1978).
- Laaksonen A. L Koskiahde V &Juva K. Dosage od antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematous. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand. J. Rheumatol. 3, 103-108.
- Jia Liu, Ruiyan Cao, Mingyue Xu, Xi Wang, Huanyu Zhang, Hengrui Hu, Yufeng Li, Zhihong Hu, Wu Zhong and Manil Wang. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery (2020)6:16.
- Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro Antiviral activity and projection of optimised dosing Design of Hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. Pii: ciaa237.
- Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. International Journal of Antimicrobial Agents – In Press 17 March 2020.
- Toledo F. Mechanisms of Action of Hydroxychloroquine in reducing risk of Type 2 Diabetes. Grantome [Internet]. [cited 2018 Jul 20]; available from http://grantome.com/grant/NIH/R21-DK082878-02.
- Solomon DH, Garg R, LuB, Todd DJ, Mercer E, Norton T, et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken). 2014 Aug;66(8):1246-51.
- Mercer E, Rekedal L, Gang R, Lu B, Massarotti EM, Solomon DH. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res There. 2012;14(3):R135.
- Bajaj S. RSSDI clinical practice recommendation for the management of type 2 diabetes mellitus 2017. Int J Diabetes Dev Ctries. 2018 Mar; 38 (Suppl1):1-115.
- Abdollah Karimi et al. Treatment of COVID-19 in Children: Iranian Expert’s Consensus Statement. Arch Pediatr Infect Dis. 2020 April; 8(2):e102400.
- National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management Rome, Italy. Infectious Disease Reports 2020; 12:8543
- National Task force on COVID-19 constituted by Indian Council of Medical Research recommendations for use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection for selected individuals issued on 22nd March 2020.
- https://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf
Corresponding Author
Dr Arjun Baidya
Associate Professor, Department of Endocrinology, NRS Medical College & Hospital, Kolkata, West Bengal, India
DOI: https://dx.doi.org/10.18535/jmscr/v8i4.18
